The therapeutic options for psoriatic arthritis (PsA) have expanded rapidly and improved patients’ pain, function, and quality of life. However, many patients do not respond to the current disease-modifying medications or cannot take them. Oral methotrexate is the leading disease-modifying antirheumatic drug used in PsA.
Expanded role for MRI and 2 recently approved treatment options. (©Gemalbarra/Shutterstock.com)